Qelbree
Payments companies reported to CMS as associated with Qelbree. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Qelbree, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Qelbree
These are the largest totals companies reported as associated with Qelbree. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Birgit Amann | Troy, MI | Child & Adolescent Psychiatry | $263,112.85 |
| Ann Childress | Las Vegas, NV | Child & Adolescent Psychiatry | $262,485.79 |
| Gregory Mattingley | Saint Charles, MO | Psychiatry | $187,593.63 |
| Andrew Cutler | Lakewood Ranch, FL | Psychiatry | $174,149.24 |
| Frank Lopez | Winter Park, FL | Neurodevelopmental Disabilities (Pediatrics) | $131,198.35 |
| Richard Jackson | Boca Raton, FL | Psychiatry | $129,092.60 |
| Michael Feld | Northbrook, IL | Psychiatry | $127,882.75 |
| Alice Mao | Houston, TX | Psychiatry | $124,551.96 |
| Rakesh Jain | Lake Jackson, TX | Psychiatry | $113,547.53 |
| James Anderson | High Point, NC | Pediatrics | $111,328.24 |
Prescribed Qelbree?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.